Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-10-09
2007-10-09
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S199100, C424S204100, C424S224100, C424S229100, C424S234100
Reexamination Certificate
active
09303040
ABSTRACT:
The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropiate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline. The present invention also comprises recombinant viruses which are capable of suppressing an immune respons in a feline.
REFERENCES:
patent: 5656275 (1997-08-01), Wasmoen et al.
patent: 5861310 (1999-01-01), Freeman et al.
patent: 6045802 (2000-04-01), Schlom et al.
patent: 6548068 (2003-04-01), Schlom et al.
patent: 6723705 (2004-04-01), Freeman et al.
patent: 2002/0028208 (2002-03-01), Collisson et al.
patent: 0 576 092 (1993-12-01), None
patent: WO 92/00092 (1992-01-01), None
patent: WO 92/15671 (1992-09-01), None
patent: WO 93/00431 (1993-01-01), None
patent: WO 94/03621 (1994-02-01), None
patent: WO 95/03408 (1995-02-01), None
patent: WO 96/03435 (1996-02-01), None
patent: WO 96/10419 (1996-04-01), None
patent: WO 96/40268 (1996-12-01), None
patent: WO 96/40915 (1996-12-01), None
patent: WO 98/04684 (1998-02-01), None
Tripathy D. N. Swinepox virus as a vaccine vector for swine pathogens. Advances in Veterinary Medicine (1999) vol. 41, pp. 463-480.
Jackson et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. Journal of Virology (2001) vol. 1205-1210.
Brunet et al., 1987,Nature, 328: 267-270.
Freeman, et al., 1993,J. Exp. Med., 178: 2185-2192.
Hash, S. M., 1997, EMBL Database Entry FCU57754, Accession No. U57754.
Hash, S. M., 1997, EMBL Database Entry FCU57755, Accession No. U57755.
Akeson, A.L., “A fluorometric assay for the quantitation of cell adherence to endothelial cells,”Journal of Immunological Methods, vol. 163, pp. 181-185 (1993).
Allison, J.P. et al., “Structure, Function, and Serology of the T-cell Antigen Receptor Complex,”Annu. Rev. Immunol., vol. 5, pp. 503-540 (1987).
Allison, J.P., “CD28-B7 interaction in T-cell activation,”Current Opinion in Immunology, vol. 6, pp. 414-419 (1994).
Anderson, P. et al., “Regulatory interactions between members of the immunoglobulin superfamily,”Immunology Today, vol. 9, Nos. 7 and 8, pp. 199-203 (1988).
Antonia, S.J. et al., “B7-1 Expression by a Non-Antigen Presenting Cell-derived Tumor,”Cancer Research, vol. 55, pp. 2253-2256 (1995).
Argyle, D.J. et al., “Nucleotide and predicted peptide sequence of feline interferon-gamma (IFN-γ),”DNA Sequence—The Journal of Sequencing and Mapping, vol. 5, pp. 169-171 (1995).
Arima, T. et al., “Inhibition by CTLA4Ig of Experimental Allergic Encephalomyelitis,”The Journal of Immunology, vol. 156, pp. 4916-4924 (1996).
Arruffo, A., et al., “Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system,”Proc. Natl. Acad. Sci. USA, vol. 84, pp. 8573-8577 (1987).
Asjo, B. et al., “A Novel Mode of Human Immunodeficiency Virus Type 1 (HIV-1) Activation: Ligation of CD28 Alone Induced HIV-1 Replication in Naturally Infected Lymphocytes,”Journal of Virology, vol. 67, No. 7, pp. 4395-4398 (1993).
Azuma, M. et al., “Functional Expression of B7/BB1 on Activated T Lymphocytes,” J. Exp. Med., vol. 177, pp. 845-850 (1993).
Azuma, M. et al., “Involvement of CD28 in MHC-Unrestricted Cytotoxicity Mediated by a Human Natural Killer Leukemia Cell Line,” TheJournal of Immunology., vol. 149, No. 4, pp. 1115-1123 (1992).
Azuma, M. et al., “Requirements for CD28-Dependent T Cell-Mediated Cytotoxicity,”The Journal of Immunology, vol. 150, No. 6, pp. 2091-2101 (1993).
Azuma, M. et al.,“B70 antigen is a second ligand for CTLA-4 and CD28,”Nature, vol. 366, pp. 76-79 (1993).
Bajorath, J. et al., “Immunoglobulin fold characteristics of B7-1 (CD80) and B7-2 (CD86),”Protein Science, vol. 3, pp. 2148-2150 (1994).
Bajorath, J. et al., “Knowledge-based model building of proteins: Concepts and examples,”Protein Science, vol. 2, pp. 1798-1810 (1993).
Balzano, C. et al., “CTLA-4 and CD28: Similar Proteins, Neighbouring Genes,”Int. J. Cancer: Supplement, vol. 7, pp. 28-32 (1992).
Barcy, S. et al., “FcR cross-linking on monocytes results in impaired T cell stimulatory capacity,”International Immunology, vol. 7, No. 2, pp. 179-189 (1995).
Beale, D., “A Comparison of the Amino Acid Sequences of the Extracellular Domains of the Immunoglobulin Superfamily. Possible Correlations Between Conservancy and Conformation,”Comp. Biochem. Physiol., vol. 80B, No. 2, pp. 181-194 (1985).
Bellone, M. et al., “In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen presenting cells,”Eur. J. Immunol., vol. 24, pp. 2691-2698 (1994).
Berke, G., “The Binding and Lysis of Target Cells by Cytotoxic Lymphocytes: Molecular and Cellular Aspects,”Annu. Rev. Immunol., vol. 12, pp. 735-773 (1994).
Berke, G., “The Functions and Mechanisms of Action of Cytolytic Lymphocytes,”Fundamental Immunology, (W. Paul), New York: Raven Publ. 3d ed., pp. 965-1014 (1993).
Boise, L.H. et al., “CD28 Costimulation Can Promote T Cell Survival by Enhancing the Expression of Bcl-xL,”Immunity, vol. 3, pp. 87-98 (1995).
Brinchmann, J.E. et al., “Expression of Costimulatory Molecule CD28 on T Cells in Human Immunodeficiency Virus Type 1 Infection: Functional and Clinical Correlations,”The Journal of Infectious Diseases, vol. 169, pp. 730-738 (1994).
Brown, W.C. et al., “Feline Immunodeficiency Virus Infects Both CD4+and CD8+T Lymphocytes,” Journal of Virology, vol. 65, No. 6, pp. 3359-3364 (1991).
Buck, C.A., “Immunoglobulin superfamily: structure, function and relationship to other receptor molecules,”Seminars in Cell Biology, vol. 3, pp. 179-188 (1992).
Buelens, C. et al., “Interleukin 10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells,”Eur. J. Immunol., vol. 25, pp. 2668-2672 (1995).
Caruso, A. et al., “Expression of CD28 on CD8+and CD4+Lymphocytes During HIV Infection,”Scand. J. Immunol., vol. 40, pp. 485-490 (1994).
Cerdan, C. et al., IL-1α is Produced by T Lymphocytes Activated Via the CD2 Plus CD28 Pathways,The Journal of Immunology, vol. 146, No. 2, pp. 560-564 (1991).
Chambers, C.A., et al., “Co-stimulation in T cell responses,”Current Opinion in Immunology, vol. 9, pp. 396-404 (1997).
Chen, L. et al., “Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4,”Cell, vol. 71, pp. 1093-1102 (1992).
Chen, L. et al., “Costimulation of T cells for tumor immunity,”Immunology Today, vol. 14, No. 10, pp. 483-486 (1993).
Chen, L. et al., “Induction of Cytotoxic T Lymphocytes Specific for a Syngeneic Tumor Expressing the E6 Oncoprotein of Human Papillomavirus Type 16,”The Journal of Immunology, vol. 148, No. 8, pp. 2716-2621 (1992).
Chesnut, R.W. et al., “Antigen Presentation by B Cells and its Significance in T-B Interactions,”Advances in Immunology, vol. 39, pp. 51-94 (1986).
Clark, S.J. et al., “High Titers of Cytopathic Virus in Plasma of Pati
Choi Insoo
Cochran Mark D.
Collisson Ellen
Hash Stephen
Winslow Barbara J.
Campell Bruce R.
Huet Sharon
Morgan & Finnegan , LLP
Schering-Plough Animal Health Corporation
Texas A & M University System
LandOfFree
Recombinant virus expressing foreign DNA encoding feline... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant virus expressing foreign DNA encoding feline..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant virus expressing foreign DNA encoding feline... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3836477